Literature DB >> 32606113

Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology.

Sylvain Raoul Simeni Njonnou1,2, Justine Deuson3, Claire Royer-Chardon4, Frédéric Alain Vandergheynst5, Virginie De Wilde3.   

Abstract

TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis or renal dysfunction and organomegaly) syndrome is a systemic inflammatory disease characterised by thrombocytopenia, anasarca, fever or inflammatory syndrome, reticulin myelofibrosis or renal dysfunction and organomegaly. It was first described as a subtype of idiopathic multicentric Castleman disease. Here, we report the case of a 42-year-old woman presenting with thrombocytopenia, anasarca, inflammatory syndrome, renal insufficiency, reticulin myelofibrosis at bone marrow biopsy and cervical and axillary lymph nodes. Kidney biopsy showed double contours of the glomerular basement membrane, mesangiolysis and endothelial swelling compatible with thrombotic microangiopathy (TMA) as well as with TAFRO syndrome. She was successfully treated by corticosteroids, tocilizumab and rituximab. This new case description of TAFRO syndrome underlines three features of this disease rarely described in the literature and never simultaneously in the same patient: the association to severe hypothyroidism, the presence of TMA-like lesions on kidney biopsy and the treatment by the association of steroids, tocilizumab and rituximab. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute renal failure; haematology (incl blood transfusion); immunological products and vaccines

Mesh:

Substances:

Year:  2020        PMID: 32606113      PMCID: PMC7328895          DOI: 10.1136/bcr-2019-234155

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  35 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?

Authors:  Shino Fujimoto; Tomoyuki Sakai; Hiroshi Kawabata; Nozomu Kurose; Sohsuke Yamada; Kazue Takai; Sadao Aoki; Junya Kuroda; Makoto Ide; Keigo Setoguchi; Norifumi Tsukamoto; Haruka Iwao-Kawanami; Takafumi Kawanami; Shuichi Mizuta; Toshihiro Fukushima; Yasufumi Masaki
Journal:  Am J Hematol       Date:  2019-06-21       Impact factor: 10.047

Review 3.  Tafro syndrome: Critical review for clinicians and pathologists.

Authors:  Semra Paydas
Journal:  Crit Rev Oncol Hematol       Date:  2018-06-06       Impact factor: 6.312

Review 4.  Castleman Disease.

Authors:  Wei Wang; L Jeffrey Medeiros
Journal:  Surg Pathol Clin       Date:  2019-05-23

5.  Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab.

Authors:  Kei Suzuki; Takeshi Matsumoto; Yoshiaki Iwashita; Ken Ishikura; Masaki Fujioka; Hideo Wada; Naoyuki Katayama; Hiroshi Imai
Journal:  Int J Hematol       Date:  2019-01-24       Impact factor: 2.490

6.  TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature.

Authors:  Malorie Simons; Emmanuel Apor; James N Butera; Diana O Treaba
Journal:  Case Rep Hematol       Date:  2016-09-29

7.  A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.

Authors:  Fabio Freire José; Lucila Nassif Kerbauy; Guilherme Fleury Perini; Danielle Isadora Blumenschein; Denise da Cunha Pasqualin; Denise Maria Avancini Costa Malheiros; Guilherme de Carvalho Campos Neto; Fabio Pires de Souza Santos; Ronaldo Piovesan; Nelson Hamerschlak
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature.

Authors:  Céline Louis; Sandrine Vijgen; Kaveh Samii; Yves Chalandon; Louis Terriou; David Launay; David C Fajgenbaum; Jörg D Seebach; Yannick D Muller
Journal:  Front Med (Lausanne)       Date:  2017-09-22

9.  Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Clin Case Rep       Date:  2018-02-21

10.  Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage.

Authors:  Yuhei Noda; Yosuke Saka; Akihisa Kato; Tetsushi Mimura; Tomohiko Naruse
Journal:  Clin Nephrol Case Stud       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.